Traditional pharmaceutical enterprises unite to create new pharmaceutical enterprises: Yunnan Baiyao's 350 million yuan cornerstone investment in Chinese antibody

[pharmaceutical network industry trends] Based on the industry development trend, after more than ten years of accumulation, China's innovative drug industry has shown a prairie fire trend From 2015 to 2017, representatives of several domestic independent innovative drugs have achieved commercial success With the deepening of pharmaceutical reform, the domestic policy environment is more conducive to the development of innovative pharmaceutical enterprises Innovative pharmaceutical will become an important and flexible main line of domestic pharmaceutical investment in the next decade Recently, there has been another big news in the field of innovative medicine That is to say, on the evening of October 25, China antibody Pharmaceutical Co., Ltd ("China antibody"), an innovative pharmaceutical company to be listed in Hong Kong, received a cornerstone investment of US $50 million (about 350 million yuan) from Yunnan Baiyao, a well-known Chinese listed pharmaceutical company It is worth mentioning that Yunnan Baiyao has become the cornerstone investor of antibody in China, and is the cornerstone investor of Yunnan Baiyao's investment in innovative pharmaceutical enterprises According to the industry, this investment will help Yunnan Baiyao expand its business in the field of innovative drugs, help Yunnan Baiyao open the door to the field of monoclonal antibodies and even innovative drugs, and is a powerful step for Yunnan Baiyao as a traditional pharmaceutical enterprise to enter the field of innovation The R & D threshold of innovative drugs, especially McAbs, is very high, which requires the integration of multi-disciplinary expertise, continuous high capital investment, strict supervision, long and complex development process, and high requirements for production technology and supply chain management Antibody in China is one of the few biotechnology companies with a complete industrial chain platform, covering the whole process of innovative drug development, including research and development, clinical trials, production and so on
The cornerstone investment of Yunnan Baiyao in China's antibody industry is conducive to the deep cooperation between the two sides in the industry, and it will be able to independently establish an innovative drug platform At the same time, Yunnan Baiyao is also expected to build an independent innovation team with the help of a team of scientists and scientific consultants with rich antibody experience in China, so as to deeply enter the innovation drug development ecosystem and the potential innovation drug market, and extract innovation New fruit According to frost Sullivan analysis, the total market size of antibody drugs in the world has exceeded 100 billion US dollars It is reported that the first phase clinical trial of sm03 in the treatment of systemic lupus erythematosus (SLE) and non Hodgkin's lymphoma (NHL) has been completed in addition to the clinical experiment and drug research and development of RA disease, and the second phase clinical trial for systemic lupus erythematosus is planned to be launched in China in 2020 Once the drug is approved by the state, Chinese antibodies can also be produced in time for drug supply to the market Innovative medicine has always stood at the top of the pyramid of the whole medical and health industry because of its high R & D threshold, wide range of studies and long time consumption Yunnan Baiyao's investment also opened a door to innovative pharmaceutical research and clinical trials It is understood that in recent years, China's large pharmaceutical companies have become a new trend in the industry to invest in innovative pharmaceutical enterprises For example, Fosun Pharmaceutical invests in Fuhong Hanlin and cultivates listed companies, China biopharmaceutical and kangfang biological establish joint ventures, Yifan pharmaceutical acquires jiannenglong, China biopharmaceutical cornerstone invests in AXA pharmaceutical, etc It is reported that these invested pharmaceutical enterprises are all innovative enterprises at the forefront of the current Chinese medical industry, and Chinese antibodies are no exception This time, Yunnan Baiyao invested in China's antibody industry, which also represents the new trend of traditional large pharmaceutical companies to invest in innovative pharmaceutical enterprises and actively seek development opportunities in the field of innovative drugs Nowadays, more and more traditional pharmaceutical enterprises begin to pay attention to some innovative enterprises from the pre IPO or even basic research stage They use abundant resources and capital strength to attract these innovative enterprises According to the industry, the marriage of traditional pharmaceutical enterprises and new innovative pharmaceutical enterprises will effectively accelerate the development of innovative products and accelerate the development of innovative pharmaceutical industry